Another, less potent, non-bile acid FXR agonist, cilofexor, showed a significant decrease in HDL cholesterol, but not in LDL cholesterol, over 12 weeks of treatment in patients with primary sclerosing cholangitis,31 and the bile acid FXR agonist OCA showed dose-dependent decreases in total and HDL cholesterol, but not in LDL cholesterol, over 12 weeks to 12 months of treatment.12 Here, NR1H4 is linked to sclerosing cholangitis.